Kerry Bennett - IDEXX Laboratories Senior Labs

IDXX Stock  USD 505.34  6.04  1.21%   

Executive

Kerry Bennett is Senior Labs of IDEXX Laboratories
Address One IDEXX Drive, Westbrook, ME, United States, 04092
Phone207 556 0300
Webhttps://www.idexx.com

IDEXX Laboratories Management Efficiency

The company has return on total asset (ROA) of 0.2283 % which means that it generated a profit of $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8074 %, meaning that it created $0.8074 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.
The company currently holds 947.88 M in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist IDEXX Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, IDEXX Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like IDEXX Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for IDEXX to invest in growth at high rates of return. When we think about IDEXX Laboratories' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Bill PriestAcadia Healthcare
N/A
Qing HuAesthetic Medical Intl
60
Mark PalmenterAcadia Healthcare
N/A
Lyn KetelsenHCA Holdings
N/A
Nasser MDAcadia Healthcare
N/A
Emily MattacchioneNovo Integrated Sciences
43
MD MBAHCA Holdings
58
Laura GroschenAcadia Healthcare
N/A
Joseph IIIHCA Holdings
67
Klara RadulyneNovo Integrated Sciences
38
Jeffrey CohenHCA Holdings
52
Frank CFAHCA Holdings
N/A
Gretchen HommrichAcadia Healthcare
N/A
Jim BrownHCA Holdings
N/A
Terence ArkelHCA Holdings
N/A
Isa DiazAcadia Healthcare
N/A
Martin PaslickHCA Holdings
64
Kirk CheneyPennant Group
N/A
Lynette CPAPennant Group
47
Kathleen JDHCA Holdings
60
Heather CPAAcadia Healthcare
52
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine. Idexx Laboratories operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 10000 people. IDEXX Laboratories (IDXX) is traded on NASDAQ Exchange in USA. It is located in One IDEXX Drive, Westbrook, ME, United States, 04092 and employs 11,000 people. IDEXX Laboratories is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

IDEXX Laboratories Leadership Team

Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathy Turner, Corporate Vice President
Sophie Vandebroek, Director
Jonathan Ayers, Chairman, CEO and Pres
William End, Lead Independent Director
Jacqueline Studer, Corporate Vice President General Counsel, Secretary
Johnny Powers, Executive VP
Rebecca Henderson, Independent Director
Michael Lane, Corporate Vice President General Manager
Anne Szostak, Independent Director
George Fennell, Senior Officer
Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary
Ken Grady, Senior Officer
Jay Mazelsky, Executive VP
Stuart Essig, Independent Director
M Szostak, Independent Director
Bruce Claflin, Independent Director
Sam Samad, Independent Director
Barry Johnson, Independent Director
Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
Nimrata PE, Sector Strategy
Martin Smith, Executive CTO
Jeffery Chadbourne, Director Reporting
Daniel Junius, Independent Director
Lawrence Kingsley, Independent Director
Kerry Bennett, Senior Labs
Thomas Craig, Independent Director
Michael Johnson, Executive Officer
Jonathan Mazelsky, CEO President
James Polewaczyk, Executive Officer
John Hart, Senior Operations
Michael Williams, Executive VP
Pat Venters, Chief Marketing Officer, Vice President
Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer

IDEXX Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

IDEXX Laboratories Investors Sentiment

The influence of IDEXX Laboratories' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in IDEXX. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to IDEXX Laboratories' public news can be used to forecast risks associated with an investment in IDEXX. The trend in average sentiment can be used to explain how an investor holding IDEXX can time the market purely based on public headlines and social activities around IDEXX Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
IDEXX Laboratories' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for IDEXX Laboratories' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average IDEXX Laboratories' news discussions. The higher the estimated score, the more favorable is the investor's outlook on IDEXX Laboratories.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards IDEXX Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, IDEXX Laboratories' short interest history, or implied volatility extrapolated from IDEXX Laboratories options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether IDEXX Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IDEXX Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Idexx Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Idexx Laboratories Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for IDEXX Stock analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stocks Directory
Find actively traded stocks across global markets
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.121
Earnings Share
10.04
Revenue Per Share
44.073
Quarterly Revenue Growth
0.088
Return On Assets
0.2283
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.